Lindsay A. Md Rosenwald Purchases 10,000 Shares of Journey Medical Co. (NASDAQ:DERM) Stock

Journey Medical Co. (NASDAQ:DERM) Director Lindsay A. Md Rosenwald bought 10,000 shares of the business’s stock in a transaction dated Monday, March 25th. The shares were purchased at an average price of $3.04 per share, for a total transaction of $30,400.00. Following the transaction, the director now directly owns 144,245 shares of the company’s stock, valued at approximately $438,504.80. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Journey Medical Stock Performance

Shares of DERM stock opened at $3.68 on Friday. The stock has a market capitalization of $68.12 million, a P/E ratio of -10.51 and a beta of 0.83. Journey Medical Co. has a 52-week low of $1.02 and a 52-week high of $8.11.

Hedge Funds Weigh In On Journey Medical

Several institutional investors have recently added to or reduced their stakes in DERM. Vanguard Group Inc. increased its position in Journey Medical by 78.1% during the 4th quarter. Vanguard Group Inc. now owns 129,448 shares of the company’s stock worth $746,000 after purchasing an additional 56,781 shares during the period. Virtu Financial LLC acquired a new position in Journey Medical during the 4th quarter worth approximately $153,000. Northern Trust Corp acquired a new position in Journey Medical during the 4th quarter worth approximately $96,000. Finally, Citadel Advisors LLC acquired a new position in Journey Medical during the 4th quarter worth approximately $65,000. Institutional investors and hedge funds own 7.25% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Alliance Global Partners assumed coverage on Journey Medical in a research report on Friday, February 16th. They issued a “buy” rating and a $8.50 price target on the stock.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Zilxi, a topical minocycline treatment for inflammatory lesions; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use.